Immatics appoints new CEO
This article was originally published in Scrip
Executive Summary
ImmaticsBiotechnologies (Germany) has appointed Paul Higham chief executive officer, effective August 1st. Mr Higham previously served as director of commercial development at Ark Therapeutics. Before that, he worked as international commercial vice-president for GI, metabolic and pain at Glaxo Wellcome from 1996 to 2001. Immatics is an independent biopharmaceutical company developing active immunotherapies against cancer.